CABs
Community advisory boards (CABs) are community engagement platforms, comprised of treatment advocates and community leaders with lived experience to review the state of treatment research, contribute to research protocols, engage in the research and development process, and meet with industry and developers about cost, pricing, and access plans.
HCV World CAB (2014-2017)
The HCV World CAB interacted with pharmaceutical and diagnostics companies that produce HCV treatment and tests to understand their access, licensing, and pricing strategies, particularly in high-burden, low- and middle-income countries.
First HCV World CAB Meeting
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
About
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More
TAG and LAT CAB Welcome Indian Patent Office Decision That Could Expand Access to Hepatitis C Treatment
TAG and the LAT CAB celebrate the Indian Patent Office’s decision to NOT grant a patent on the HCV combination treatment glecaprevir/pibrentasvir, aka Mavyret® or Maviret® manufactured by AbbVie. More
